Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology
Gaia Griguolo(University of North Carolina at Chapel Hill), Amélie Darlix(Institut de Recherche en Cancérologie de Montpellier), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Nelly Firmin(Inserm), Stéphane Pouderoux(Institut de Recherche en Cancérologie de Montpellier), Marie Viala(Institut de Recherche en Cancérologie de Montpellier), William Jacot(Inserm), C. Bourgier(Inserm), Maria Vittoria Dieci(Istituto Oncologico Veneto), Federica Miglietta(University of Padua)
Cited by 45
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k